Microbiota-mediated modulation of the tumor microenvironment in urological cancers: crosstalk between gut and intratumoral microbiota
5 affiliations
- 1Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 511430 China
- 2NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, People’s Republic of China
- 3Department of Surgery, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA USA
- 4Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, People’s Republic of China
- 5Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People’s Republic of China
Abstract
Recent studies indicate the gut microbiome as a crucial regulator of cancer therapy, yet its role in urological malignancies remains incompletely understood. High rates of resistance to cornerstone treatments, including immune checkpoint inhibitors (ICIs) and intravesical immunotherapy, represent major clinical hurdles. Synthesizing emerging evidence on the gut–tumor axis shows how the gut, urobiome, and intratumoral microbiota (IM) collectively influence the tumor microenvironment (TME) and therapeutic outcomes. This influence extends beyond chronic inflammation and direct genotoxicity to include metabolic crosstalk that shapes the host immune landscape. The composition of the gut microbiota is emerging as a potential predictive marker for ICI efficacy, as the enrichment of certain beneficial taxa has been linked to favorable outcomes. Microbial metabolic pathways are also implicated in therapeutic resistance; microbial metabolism of host hormonal precursors is hypothesized as one mechanism contributing to resistance to endocrine therapies. Furthermore, systemic and local communities may interact, wherein gut-derived metabolites can enhance systemic immunotherapy, while the local urobiome may interfere with intravesical treatment efficacy. However, clinical translation faces major impediments. A primary challenge is the lack of methodological standardization, which generates observational inconsistencies and complicates causal inference. Future progress will therefore depend on large-scale, longitudinal, multiomics clinical trials using harmonized protocols. This review provides a comparative narrative synthesis of shared and distinct mechanisms across the three major urological cancers and outlines priorities for future interventions and precision medicine in urologic oncology.
Related
- Intratumoral microbiota and their emerging role in the tumor microenvironment.
- Intratumoral microbiota: bidirectional modulation of tumor radiosensitivity
- Intratumoral microbiota heterogeneity and Bifidobacterium abundance are linked to very early recurrence in hepatocellular carcinoma
- Gut microbiota composition and dysbiosis signatures associated with complex gastrointestinal and urological conditions in neonates: a case series study
- Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions
BibTeX
@article{li2026microbiotamediated,
title = {{Microbiota-mediated modulation of the tumor microenvironment in urological cancers: crosstalk between gut and intratumoral microbiota}},
author = {Zhibiao Li and Haoxiang Xu and Lin Yang and Jun Zheng and Weijia Li and Rulin Liao and Wenxue Huang and Boyuan Sun and Zhuohang Li and Cunzhen Ma and Xunguo Yang and Peidan Peng and Jie Zhao and Bisheng Cheng and Peng Wu},
journal = {Cellular \& Molecular Biology Letters},
year = {2026},
month = jul,
doi = {10.1186/s11658-026-00951-7},
url = {https://doi.org/10.1186/s11658-026-00951-7},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Microbiota-mediated modulation of the tumor microenvironment in urological cancers: crosstalk between gut and intratumoral microbiota
AU - Zhibiao Li
AU - Haoxiang Xu
AU - Lin Yang
AU - Jun Zheng
AU - Weijia Li
AU - Rulin Liao
AU - Wenxue Huang
AU - Boyuan Sun
AU - Zhuohang Li
AU - Cunzhen Ma
AU - Xunguo Yang
AU - Peidan Peng
AU - Jie Zhao
AU - Bisheng Cheng
AU - Peng Wu
PY - 2026
DA - 2026/07/09
JO - Cellular & Molecular Biology Letters
DO - 10.1186/s11658-026-00951-7
UR - https://doi.org/10.1186/s11658-026-00951-7
AB - Recent studies indicate the gut microbiome as a crucial regulator of cancer therapy, yet its role in urological malignancies remains incompletely understood. High rates of resistance to cornerstone treatments, including immune checkpoint inhibitors (ICIs) and intravesical immunotherapy, represent major clinical hurdles. Synthesizing emerging evidence on the gut–tumor axis shows how the gut, urobiome, and intratumoral microbiota (IM) collectively influence the tumor microenvironment (TME) and therapeutic outcomes. This influence extends beyond chronic inflammation and direct genotoxicity to include metabolic crosstalk that shapes the host immune landscape. The composition of the gut microbiota is emerging as a potential predictive marker for ICI efficacy, as the enrichment of certain beneficial taxa has been linked to favorable outcomes. Microbial metabolic pathways are also implicated in therapeutic resistance; microbial metabolism of host hormonal precursors is hypothesized as one mechanism contributing to resistance to endocrine therapies. Furthermore, systemic and local communities may interact, wherein gut-derived metabolites can enhance systemic immunotherapy, while the local urobiome may interfere with intravesical treatment efficacy. However, clinical translation faces major impediments. A primary challenge is the lack of methodological standardization, which generates observational inconsistencies and complicates causal inference. Future progress will therefore depend on large-scale, longitudinal, multiomics clinical trials using harmonized protocols. This review provides a comparative narrative synthesis of shared and distinct mechanisms across the three major urological cancers and outlines priorities for future interventions and precision medicine in urologic oncology.
SN - 1425-8153
SN - 1689-1392
ER -